Literature DB >> 3147475

"Paradoxical" analgesia induced by naloxone and naltrexone.

J D Greeley1, A D Lê, C X Poulos, H Cappell.   

Abstract

Analgesic effects of pellet implantation of the opiate antagonists naloxone and naltrexone and of chronic administration of naloxone by subcutaneous injection were examined. Rats were implanted with a slow-release pellet containing 10 mg naloxone or 10 mg naltrexone and tested for paw-lick latency on a hotplate apparatus. Controls were implanted with placebo pellets or given saline injections as appropriate. There were five test trials at intervals up to 72 h after implantation of naloxone and up to 120 h after the implantation of naltrexone. In a separate experiment, 5 mg/kg naloxone was injected; there were single trials on 5 consecutive days. All drug-treated animals displayed clear and substantial analgesia by their second test trial. This "paradoxical" analgesia was gradually reversed in the pellet-implant groups as tissue levels of the antagonists declined, but increased progressively with each trial involving injections. It was hypothesized that blockade of endogenous opiates by antagonists resulted in a form of "super-pain" on the hotplate, which in turn activated a normally redundant "backup" analgesic system. The results with naloxone injections show that unlike opiate-mediated analgesia, this hypothetical system is resistant to tolerance.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3147475     DOI: 10.1007/bf02431530

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  14 in total

1.  An improved long-acting delivery system for narcotic antagonists.

Authors:  A L Misra; R B Pontani
Journal:  J Pharm Pharmacol       Date:  1978-05       Impact factor: 3.765

2.  Activation and expression of endogenous pain control mechanisms in rats given repeated nociceptive tests under the influence of naloxone.

Authors:  J Rochford; J Stewart
Journal:  Behav Neurosci       Date:  1987-02       Impact factor: 1.912

3.  Morphine analgesic tolerance: its situation specificity supports a Pavlovian conditioning model.

Authors:  S Siegel
Journal:  Science       Date:  1976-07-23       Impact factor: 47.728

4.  Opiate receptor supersensitivity produced by chronic naloxone treatment: dissociation of morphine-induced antinociception and conditioned taste aversion.

Authors:  M T Bardo; J S Miller; M E Risner
Journal:  Pharmacol Biochem Behav       Date:  1984-10       Impact factor: 3.533

5.  Enhancement of a nociceptive reaction by opioid antagonists in mice.

Authors:  J J Jacob; K Ramabadran
Journal:  Br J Pharmacol       Date:  1978-09       Impact factor: 8.739

6.  Antagonism of stimulation-produced analgesia by naloxone, a narcotic antagonist.

Authors:  H Akil; D J Mayer; J C Liebeskind
Journal:  Science       Date:  1976-03-05       Impact factor: 47.728

7.  Pharmacodynamic supersensitivity and opioid receptor upregulation in the mouse.

Authors:  B C Yoburn; F A Nunes; B Adler; G W Pasternak; C E Inturrisi
Journal:  J Pharmacol Exp Ther       Date:  1986-10       Impact factor: 4.030

8.  Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation.

Authors:  A Tempel; E L Gardner; R S Zukin
Journal:  J Pharmacol Exp Ther       Date:  1985-02       Impact factor: 4.030

9.  Endogenous opioid peptides: multiple agonists and receptors.

Authors:  J A Lord; A A Waterfield; J Hughes; H W Kosterlitz
Journal:  Nature       Date:  1977-06-09       Impact factor: 49.962

10.  Naloxazone and pain-inhibitory systems: evidence for a collateral inhibition model.

Authors:  A L Kirchgessner; R J Bodnar; G W Pasternak
Journal:  Pharmacol Biochem Behav       Date:  1982-12       Impact factor: 3.533

View more
  9 in total

1.  Effects of hypophysectomy and adrenalectomy on naloxone-induced analgesia.

Authors:  H Foo; R F Westbrook
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 2.  Indications for Opioid Antagonists.

Authors:  O J Michael Coppes; Christine N Sang
Journal:  Curr Pain Headache Rep       Date:  2017-06

3.  Clonidine and yohimbine modulate the effects of naloxone on novelty-induced hypoalgesia.

Authors:  J Rochford; P Dawes
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

4.  Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment.

Authors:  S M Crain; K F Shen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

5.  Naloxone-induced analgesia and morphine supersensitivity effects are contingent upon prior exposure to analgesic testing.

Authors:  C X Poulos; D M Knoke; A D Le; H Cappell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

6.  Absence of opioid stress-induced analgesia in mice lacking beta-endorphin by site-directed mutagenesis.

Authors:  M Rubinstein; J S Mogil; M Japón; E C Chan; R G Allen; M J Low
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

7.  Effects of acute selective 5-HT1, 5-HT2, 5-HT3 receptor and alpha 2 adrenoceptor blockade on naloxone-induced antinociception.

Authors:  M J Walker; C X Poulos; A D Le
Journal:  Psychopharmacology (Berl)       Date:  1994-01       Impact factor: 4.530

8.  Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids.

Authors:  Michael A Ueberall; Gerhard Hh Mueller-Schwefe
Journal:  J Pain Res       Date:  2015-08-10       Impact factor: 3.133

Review 9.  The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.

Authors:  Jarred Younger; Luke Parkitny; David McLain
Journal:  Clin Rheumatol       Date:  2014-02-15       Impact factor: 2.980

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.